TY - JOUR
T1 - Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma
AU - Grottoli, S.
AU - Gasco, V.
AU - Broglio, F.
AU - Baldelli, R.
AU - Ragazzoni, F.
AU - Gallenca, F.
AU - Mainolfi, A.
AU - Prodam, F.
AU - Muccioli, G.
AU - Ghigo, E.
PY - 2006/4
Y1 - 2006/4
N2 - Context: Cortistatin binds all somatostatin receptor subtypes but also has particular central actions; moreover, a specific cortistatin receptor has also been discovered. Objective: We compared the endocrine effects of cortistatin-17 with those of somatostatin-14 in patients with acromegaly (ACRO) or prolactinoma (PRLOMA). Normal subjects (NS) were studied as control group. Design: All subjects underwent the following tests: 1) saline, 2) somatostatin-14 (2.0 μg/kg·h iv, 0-120 min) and 3) cortistatin-17 (2.0 μg/kg·h iv, 0-120 min) infusion. Results: Cortistatin-17 and somatostatin-14 inhibited GH secretion to the same extent in ACRO (P < 0.05) and NS (P < 0.01). Cortistatin-17 and somatostatin-14 inhibited PRL secretion in PRLOMA (P < 0.05), to some extent in ACRO (P value not significant), but not in NS. Insulin secretion was inhibited by both cortistatin-17 and somatostatin-14 to the same extent in all groups (P < 0.05). Conclusions: Cortistatin-17 and somatostatin-14 display the same effects on GH, PRL, and insulin secretion in patients with ACRO or PRLOMA.
AB - Context: Cortistatin binds all somatostatin receptor subtypes but also has particular central actions; moreover, a specific cortistatin receptor has also been discovered. Objective: We compared the endocrine effects of cortistatin-17 with those of somatostatin-14 in patients with acromegaly (ACRO) or prolactinoma (PRLOMA). Normal subjects (NS) were studied as control group. Design: All subjects underwent the following tests: 1) saline, 2) somatostatin-14 (2.0 μg/kg·h iv, 0-120 min) and 3) cortistatin-17 (2.0 μg/kg·h iv, 0-120 min) infusion. Results: Cortistatin-17 and somatostatin-14 inhibited GH secretion to the same extent in ACRO (P < 0.05) and NS (P < 0.01). Cortistatin-17 and somatostatin-14 inhibited PRL secretion in PRLOMA (P < 0.05), to some extent in ACRO (P value not significant), but not in NS. Insulin secretion was inhibited by both cortistatin-17 and somatostatin-14 to the same extent in all groups (P < 0.05). Conclusions: Cortistatin-17 and somatostatin-14 display the same effects on GH, PRL, and insulin secretion in patients with ACRO or PRLOMA.
UR - http://www.scopus.com/inward/record.url?scp=33646042271&partnerID=8YFLogxK
U2 - 10.1210/jc.2005-1837
DO - 10.1210/jc.2005-1837
M3 - Article
SN - 0021-972X
VL - 91
SP - 1595
EP - 1599
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 4
ER -
